C-PROWESS study

Interventions: Combination therapy of panitumumab plus irinotecan: Patients receive panitumumab (intravenous dose of 6 mg/kg) plus intraveous infusion of irinotecan of 150 mg/m2 (body surface area). Treatment cycles are repeated every 2 weeks until disease progression, unacceptable adverse events, or withdrawal of consent. Primary outcome(s): Response Rate Study Design: single arm study, open(masking not used), no treatment control/standard of care control, single assignment, treatment purpose